By Fineline Cube The State Council released the “Opinions on Improving the Drug Pricing Mechanism” this week, introducing sweeping reforms to refine China’s market-oriented drug pricing framework, establish clear differentiation between drug innovation tiers, and strengthen the multi-tiered medical insurance system while expanding payment channels for innovative therapies.
Policy Framework Overview
| Reform Area | Key Provisions |
|---|---|
| Pricing Mechanism | Enhanced market-oriented approach with manufacturer self-assessment system for newly launched drugs |
| Drug Classification | Clear differentiation between high-innovative drugs, modified drugs, and generic drugs |
| Procurement Requirements | All drugs used by public medical institutions must be procured through provincial-level platforms |
| Markup Policy | Zero markup mandated for all drugs (excluding traditional Chinese medicine decoction pieces); extended to TCM formula granules |
Implementation Structure
New Drug Pricing System
- Self-Assessment Framework: Manufacturers implement self-assessment for newly launched drugs
- Initial Listing: New drugs listed online at initial offering prices
- Policy Support: Government guidance provided for appropriate pricing of different drug categories
- Dynamic Adjustment: Improved system for ongoing price adjustments based on market conditions
Procurement & Reimbursement Integration
- Volume-Based Procurement (VBP): Drugs included in VBP listed at agreed-upon negotiated prices
- National Reimbursement Drug List (NRDL): Negotiated and bidding drugs listed at agreed prices
- Other Drugs: Marketing authorization holders determine listing prices per established rules and price comparison frameworks
Innovation Incentive Measures
The policy explicitly aims to support pharmaceutical innovation through multiple mechanisms:
- Multi-Party Negotiations: Expanded stakeholder involvement in innovative drug price negotiations
- Payment Channel Diversification: Broader reimbursement pathways for innovative therapies
- Commercial Insurance Integration: Enhanced role for commercial health insurance in covering innovative drugs
- Charitable Initiatives: Leveraging charitable programs to improve patient access
Real-World Evidence Framework
A comprehensive real-world research infrastructure will be established to support evidence-based pricing and reimbursement decisions:
- Framework Enhancement: Improved rules, procedures, and standards for real-world drug research
- Research Prioritization: Encouragement of real-world studies on NRDL and commercial insurance catalog drugs
- Value Assessment: Scientific and objective evaluation of drug value using real-world data
- Policy Integration: Real-world evidence to inform dynamic adjustment of medical insurance catalogs and payment standards
Strategic Implications
For Pharmaceutical Companies
- Innovation Premium: Clear differentiation between high-innovative, modified, and generic drugs creates pricing tier structure
- Market Access Clarity: Transparent procurement and pricing rules reduce regulatory uncertainty
- Reimbursement Opportunities: Multiple payment channels improve commercial prospects for innovative therapies
- Evidence Generation: Real-world research requirements create both challenges and opportunities for robust value demonstration
For Healthcare System
- Cost Control: Zero markup policy and centralized procurement maintain affordability
- Quality Assurance: Market-oriented mechanisms reward genuine innovation while controlling generic drug costs
- Access Improvement: Multi-tiered insurance system expands patient access to innovative therapies
- System Efficiency: Dynamic pricing adjustments ensure optimal resource allocation
Industry Outlook
This comprehensive reform represents a maturation of China’s pharmaceutical policy framework, balancing cost containment objectives with innovation incentives. The explicit recognition of different drug innovation tiers acknowledges that not all new drugs provide equal therapeutic value, creating a more sophisticated pricing environment.
The integration of real-world evidence into pricing and reimbursement decisions aligns China with international best practices, while the expansion of commercial insurance roles reflects the government’s strategy to develop sustainable multi-payer healthcare financing.
For multinational and domestic pharmaceutical companies, the policy creates a more predictable regulatory environment with clear pathways for market access, while maintaining pressure on pricing through competitive procurement mechanisms.
Forward-Looking Statements
This brief contains forward-looking statements regarding policy implementation, market dynamics, and regulatory impacts of China’s drug pricing reforms. Actual outcomes may differ due to risks including implementation timelines, stakeholder adoption rates, competitive responses, and evolving healthcare policy priorities in China’s rapidly transforming pharmaceutical market.-Fineline Info & Tech